 Studies suggest that the blocking of IL-23, rather than IL-12, has the greatest effect on the therapeutic benefits of ustekinumab.When the patent period of a drug ends, a generic version is usually made.With conventional small-molecule drugs, it is possible to create a generic that is exactly the same as the original because small-molecule drugs can be characterized down to a single atom.